Embera NeuroTherapeutics Inc., a Shreveport-based specialty pharmaceutical company, announced Monday it has secured $4.5 million in financing.

Embera is developing treatments to help people stop smoking as well as treatments for other addictions. The company will use the money along with development grant funding from the National Institute for Drug Abuse to support clinical development of Embera’s EMB-001 through a Phase 1 study for smokers and cocaine addicts. Phase 1 studies are designed to show the drug is safe for people to take.